Business & regional news

Month Year

Email alerts

Nov 20, 2024

Medtronic begins multicenter study to address health disparities in structural heart disease care

Collaboration with health technology company Tempus seeks to identify causes for undertreatment of minority patients with heart valve disease who may benefit from minimally invasive therapies
- Structural Heart and Aortic
Oct 24, 2024

Medtronic receives CE Mark for Evolut™ FX+ TAVI system for treatment of symptomatic severe aortic stenosis

Newest-generation Evolut TAVI system builds on its market leading valve performance and durability with enhanced coronary access
- Structural Heart and Aortic
Jun 7, 2024

New data for Medtronic CoreValve/Evolut TAVR™ Systems reinforces excellent valve performance

New York Valves 2024: Late-breaking data included a SMART Trial secondary analysis showing significantly less bioprosthetic valve dysfunction with Evolut TAV across the entire range of small annulus areas when compared with the Edwards Sapien 3™ TAV platform, and CoreValve-Evolut pooled analysis demonstrating valve performance and durability benefits versus surgery.
- Structural Heart and Aortic
May 4, 2024

SCAI 2024: Medtronic transcatheter therapies show excellent outcomes in the treatment of congenital heart disease and severe aortic stenosis

Medtronic, the global leader in healthcare technology, today announced the release of important clinical outcomes in two leading transcatheter valve therapies. The results for these studies were...
- Structural Heart and Aortic
Mar 11, 2024

New late-breaking data from Medtronic Evolut™ Low Risk Trial demonstrate strong clinical and cost-effectiveness benefits of TAVR platform

CRT 2024: Evolut TAVR is a safe, effective, and economically cost-effective treatment option for low-risk severe aortic stenosis patients compared to surgery up to four years
- Structural Heart and Aortic

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa